Filing Details
- Accession Number:
- 0001209191-20-008074
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-02-10 18:19:44
- Reporting Period:
- 2020-02-06
- Accepted Time:
- 2020-02-10 18:19:44
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1396814 | Pacira Biosciences Inc. | PCRX | Pharmaceutical Preparations (2834) | 510619477 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1545439 | Bullaro Lauren Riker | C/O Pacira Biosciences, Inc. 5 Sylvan Way, Suite 300 Parsippany NJ 07054 | Vice President, Finance | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2020-02-06 | 830 | $10.81 | 11,294 | No | 4 | M | Direct | |
Common Stock | Disposition | 2020-02-06 | 830 | $46.81 | 10,464 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2020-02-07 | 170 | $10.81 | 10,634 | No | 4 | M | Direct | |
Common Stock | Disposition | 2020-02-07 | 170 | $46.81 | 10,464 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2020-02-06 | 830 | $0.00 | 830 | $10.81 |
Common Stock | Stock Option (Right to Buy) | Disposition | 2020-02-07 | 170 | $0.00 | 170 | $10.81 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
26,990 | 2022-06-05 | No | 4 | M | Direct | |
26,820 | 2022-06-05 | No | 4 | M | Direct |
Footnotes
- The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
- The option vested and became exercisable as to 25% of the option shares on June 5, 2013 and vested as to the remaining shares in successive equal monthly installments for the subsequent 36 months.